Do tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa?
The objective of this study was to assess the performance of 4 biologic tests designed to detect recent HIV-1 infections in estimating incidence in West Africa (BED, Vironostika, Avidity, and IDE-V3). These tests were assessed on a panel of 135 samples from 79 HIV-1-positive regular blood donors from Abidjan, Côte d'Ivoire, whose date of seroconversion was known (Agence Nationale de Recherches sur le SIDA et les Hépatites Virales 1220 cohort). The 135 samples included 26 from recently infected patients (< or =180 days), 94 from AIDS-free subjects with long-standing infection (>180 days), and 15 from patients with clinical AIDS. The performance of each assay in estimating HIV incidence was assessed through simulations. The modified commercial assays gave the best results for sensitivity (100% for both), and the IDE-V3 technique gave the best result for specificity (96.3%). In a context like Abidjan, with a 10% HIV-1 prevalence associated with a 1% annual incidence, the estimated test-specific annual incidence rates would be 1.2% (IDE-V3), 5.5% (Vironostika), 6.2% (BED), and 11.2% (Avidity). Most of the specimens falsely classified as incident cases were from patients infected for >180 days but <1 year. The authors conclude that none of the 4 methods could currently be used to estimate HIV-1 incidence routinely in Côte d'Ivoire but that further adaptations might enhance their accuracy.
Sakarovitch
Charlotte
C
INSERM EMI 03 38, Institut de Santé Publique, Epidémiologie, et Développement (ISPED), Université Victor Segalen Bordeaux 2, Bordeaux, France. charlotte.sakarovitch@yahoo.fr
Rouet
Francois
F
Murphy
Gary
G
Minga
Albert K
AK
Alioum
Ahmadou
A
Dabis
Francois
F
Costagliola
Dominique
D
Salamon
Roger
R
Parry
John V
JV
Barin
Francis
F
D015492:AIDS Serodiagnosis / Q000379:methods*; D000349:Africa / Q000453:epidemiology; D001681:Biological Assay; D015331:Cohort Studies; D015658:HIV Infections / Q000175:diagnosis / Q000453:epidemiology* / Q000276:immunology; D006679:HIV Seropositivity; D015528:HIV Seroprevalence; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007124:Immunoenzyme Techniques; D015994:Incidence; D011159:Population Surveillance; D015995:Prevalence; D012372:ROC Curve; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013997:Time Factors